Summary
A bioRxiv preprint identifies phosphatidylinositol (PI) as the preferred direct substrate of the enzyme PLCXD2. In a PLCXD2-deficient retinal model, the loss was associated with altered lipid products, synaptic abnormalities, retinal-layer thinning and weaker electrical responses from photoreceptors.
A bioRxiv preprint reports that PLCXD2, a mammalian phospholipase C enzyme, preferentially breaks down phosphatidylinositol (PI) rather than the phosphoinositide PI(4,5)P2 that had been associated with its activity. The study also links PLCXD2 to lipid balance in the retina and to the structural and electrical integrity of photoreceptor cells.
The findings come from cellular lipidomics, biochemical experiments with recombinant enzyme and a PLCXD2-deficient retinal model. The work is a preprint, so it represents preliminary research rather than a clinical finding.
PLCXD2’s preferred lipid substrate
Phosphatidylinositol is a membrane phospholipid that can also serve as the starting material for phosphorylated signalling lipids known as phosphoinositides. Phospholipase C enzymes cleave phospholipids, helping regulate the composition and signalling behaviour of cell membranes.
PLCXD2 activity has previously been associated with depletion of PI(4,5)P2, a phosphorylated form of PI. However, the enzyme’s preferred direct substrate had remained unresolved, according to the researchers.
In the new study, active PLCXD2 reduced the abundance of the major PI 38:4 species in cells. Changes in other phosphoinositides were more modest, while diacylglycerol (DAG) and phosphatidic acid (PA) increased. When the researchers tested recombinant PLCXD2 against substrates with matching acyl chains, the enzyme hydrolysed PI substantially more efficiently than PI(4,5)P2 and most of the other phosphoinositides tested.
Together, these experiments led the authors to classify PLCXD2 as a PI-preferring mammalian phospholipase C. That distinction matters because identifying an enzyme’s direct substrate helps connect its molecular activity to the lipid changes observed in cells.
Effects in the retina
The researchers then examined retinas lacking Plcxd2. In this model, overall PI abundance was preserved, but DAG and PA levels were reduced. The study did not find broad changes across the major membrane-phospholipid classes, suggesting that the most prominent effects were concentrated in particular lipid pools rather than involving a general collapse of membrane composition.
PLCXD2 loss was associated with early structural abnormalities at the synaptic interface between photoreceptors and bipolar cells. These changes were followed by thinning of the outer nuclear layer, the retinal layer containing photoreceptor cell bodies. The deficient retinas also showed reduced electroretinographic a-wave responses, an electrical measure linked to photoreceptor activity.
The sequence of findings connects PLCXD2’s lipid-processing activity with retinal structure and function: the enzyme helps maintain specific lipid products in the retina, and its absence is associated with changes at photoreceptor synapses, retinal-layer organisation and electrical responses.
The study is focused on cellular, biochemical and retinal-model evidence. It provides a biological framework for investigating PLCXD2 and retinal lipid disorders, but it does not report a human study or a treatment intervention. The preprint also leaves open how PLCXD2 is regulated in human retinal tissue and whether altering its activity could be therapeutically useful.